Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

129 results about "Polyethylene Terephthalates" patented technology

Polyethylene terephthalate is a polyester material that is most often used to make fibers, parts made by injection molding, and containers for food and beverages, pharmaceuticals and make-up. This material may also be recycled to make carpeting or fiber filling.

Barrier film

A barrier composition which is injection mouldable and able to be made into a transparent film or incorporated (by co-extrusion and / or lamination) into multi-layer film products, the composition on dry basis: a) from 45 to 90% by weight of a starch and / or a modified starch selected from starches modified by reaction with a hydroxyl alkyl group, an acetate or a dicarboxylic acid anhydride or a grafting polymer; b) from 4 to 12% by weight of a water soluble polymer selected from polyvinyl alcohol, polyvinylacetate, and copolymers of ethylene and vinylalcohol which have a melting point compatible with the molten state of the starch components c) from 5 to 45% by weight of a non-crystallising mixture of sorbitol and at least one other plasticizer selected from glycerol, maltitol, xylitol, mannitol, glycerol trioleate, epoxidised linseed or soybean oil, tributyl citrate, acetyl tri-ethyl citrate, glyceryl triacetate, 2,2,4-trimethyl-1,3-pentanediol diisobutyrate; polyethylene oxide or polyethylene glycol; d) from 0.3 to 2.5% by weight of a C12-22 fatty acid or salt; e) from 0.25% to 3% of an emulsifier system having a hydrophilic lipophilic balance value between 2 and 10. The barrier film may be co-injection moulded with polyethylene terephthalate (PET) or polylactic acid (PLA) for blow moulding into beverage bottles, with polyethylene (PE) or polypropylene (PP) or biodegradable polymers for high gas-barrier containers or closures, or may be co-extruded with polyethylene, polypropylene or polylactic acid for thin film packaging applications or for blow-moulded containers.
Owner:PLANTIC TECH

Polyethylene terephthalate and polyurethane composite artificial blood vessel and preparation thereof

The invention discloses a polyethylene terephthalate and polyurethane composite artificial blood vessel and a preparation method thereof, belonging to the field of biomedical engineering. The artificial blood vessel is prepared from polyethylene terephthalate and polyurethane by means of an electrostatic spinning device with a stirrer. The prepared artificial blood vessel is a tubular object witha microporous structure. The polyurethane added in the artificial blood vessel can improve the elasticity of the blood vessel under the condition of not damaging the strength of the polyethylene terephthalate material, increase the compliance of the artificial blood vessel and achieve the requirements of clinical use. The polyethylene terephthalate and polyurethane composite artificial blood vessel has the advantages of high strength, large elasticity and compliance, good biocompatibility, strong anticoagulant property and large cell adhesion, and can meet the requirements of the clinical useof the artificial blood vessels with large diameter and small diameter. The preparation process is simple and practical, and applicable to preparing the artificial blood vessels with various different requirements on mechanical properties.
Owner:宁波贝昂生物材料有限公司

PET degradation biocatalyst and application thereof

Aiming at the problems of polyethylene terephthalate (PET) plastic degradation in the prior art, the invention provides a novel PET degradation biocatalyst and a construction method thereof. The PET degradation whole-bacterium catalyst is obtained by expressing PET enzyme in a heat-resistant strain; the PET enzyme has a sequence of SEQ NO.1 or a sequence with similarity of 99% with the sequence ofSEQ NO.1; and the heat-resistant strain is clostridium thermofibrillae. The construction method of the PET degradation whole-bacterium catalyst comprises the following steps: (1) expressing PET degradation enzyme by a plasmid; (2) expressing PET degradation enzyme by a genome; and (3) expressing PET degradation bodies. The PET degradation whole-bacterium catalyst overcomes the problem of feedbackinhibition, not only has degradation efficiency obviously higher than a known whole-bacterium biodegradation system, but also has a culture condition free of aeration and stirring as an anaerobic microorganism, so that process cost is obviously reduced. In addition, simultaneous degradation of fibers and PET in a blended fabric is realized through a one-pot method; the reaction temperature is low, early-stage separation of fibers is not needed, and an additional carbon source is not needed in a degradation process, so that the PET degradation whole-bacterium catalyst has remarkable economy and efficiency.
Owner:QINGDAO INST OF BIOENERGY & BIOPROCESS TECH CHINESE ACADEMY OF SCI

Preparation method of graphene-modified polyethylene terephthalate (PET) blend fiber

The invention relates to the field of chemical fiber. Aiming at the problem of poor dispersibility in the graphene-modified fiber process in the prior art, the invention discloses a preparation methodof a graphene-modified polyethylene terephthalate (PET) blend fiber. The preparation method of the graphene-modified PET blend fiber comprises the following preparation steps of (1) modifying graphene by using a cationic modifier; (2) preparing graphene-modified slices: blending the modified cationic graphene, a modifier and PET slice powder; (3) melting: melting PET slices and the graphene-modified slices; (4) blending: spraying two spinning melts from a composite spinneret so as to form the blend fiber; and (5) carrying out aftertreatment: cooling, oiling, stretching for setting and windingthe blend fiber. Through improving the dispersibility of a graphene slice layer, the uniformity of the graphene in the composite fiber is improved, the graphene-modified PET composite fiber with an excellent performance is obtained, and the fiber has a favorable mechanical property; and through spinning the graphene masterbatch slices and the PET slices through the composite spinneret, the four-leaf clover-shaped composite fiber is prepared.
Owner:浙江双兔新材料有限公司

Composite material capable of slowly releasing antibacterial components, preparation method thereof and antibacterial slow-release bag

The invention relates to the technical field of preparation of antibacterial film materials, and particularly discloses a composite material capable of slowly releasing antibacterial components, a preparation method thereof and an antibacterial slow-release bag. The preparation method of the composite material capable of slowly releasing the antibacterial component comprises the following steps: S11, mixing a porous adsorption material with antibacterial essential oil to obtain a porous adsorption material adsorbed with the essential oil; and S12, mixing the porous adsorption material adsorbed with the essential oil with the gelatinized starch to obtain the antibacterial slow-release material. The composite material capable of slowly releasing the antibacterial component prepared by the method can continuously release the essential oil antibacterial component for more than 4 months, and in the best embodiment, the continuous release time of the essential oil antibacterial component reaches 9 months. Furthermore, the composite material capable of slowly releasing the antibacterial components is wrapped in a breathable film bag made of PET (polyethylene terephthalate), PE (polyethylene), PA (polyamide) or PP (polypropylene) to prepare the antibacterial slow-release bag, and the antibacterial slow-release bag can be widely applied to various environments needing antibiosis.
Owner:广州暨明科技有限公司

68Ga-NODAGA-cyclic polypeptide FG01 targeting EphA2 receptor as well as preparation method and application of 68Ga-NODAGA-cyclic polypeptide FG01

The invention relates to 68Ga-NODAGA-cyclic polypeptide FG01 of a targeted EphA2 receptor as well as a preparation method and application of the 68Ga-NODAGA-cyclic polypeptide FG01. The 68Ga-NODAGA-cyclic polypeptide FG01 forms an amido bond through an amino group of lysine in an amino acid sequence and a carboxyl group of serine, then an amino group at an amino terminal of the cyclic polypeptide FG01 and a coupling agent NODAGA-NHS are subjected to a condensation reaction, a chelating agent NODAGA in the cyclic polypeptide conjugate NODAGA-FG01 is chelated with 68Ga, and the 68Ga-labeled cyclic polypeptide conjugate is constructed. The invention verifies that the annular polypeptide FG01 has no obvious inhibition effect on tumor cells, indicates that the annular polypeptide FG01 has no cytotoxicity, and finds that the 68Ga-NODAGA-annular polypeptide FG01 of a targeted EphA2 receptor can be used for in-vivo imaging of EphA2 high-expression tumors, realizes molecular imaging of the EphA2 high-expression tumors such as non-small cell lung cancer by utilizing PET (Polyethylene Terephthalate), and is widely used as a tumor molecular imaging agent.
Owner:QILU UNIV OF TECH

PD-L1-targeting polypeptide PET molecular imaging probe as well as preparation method and application thereof

The invention relates to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, in particular to a PD-L1 targeting polypeptide PET molecular imaging probe and a preparation method and application thereof. The < 18 > F-AlF-NOTA-PA2881 probe is an annular polypeptide PET (Polyethylene Terephthalate) molecular imaging probe composed of ten amino acids based on Cyclopetide 66, and is formed by connecting a bifunctional chelating agent to lysine in cyclic peptide and then labeling with radionuclide < 18 > F. The invention also discloses a preparation method of the < 18 > F-AlF-NOTA-PA2881 probe. And by adopting the short-half-life radionuclide 18F marker, the tumor focus can be quickly and accurately identified. Compared with the existing mainstream monoclonal antibody imaging probe, the molecular imaging probe has the advantages that the metabolism is rapid, and the potential influence of radionuclides and monoclonal antibodies on organisms is further reduced. By means of in-vitro imaging equipment PET, the expression level of tumor cells PD-L1 can be reflected, the immunotherapy curative effect aiming at the signal channel can be predicted, real-time curative effect detection, prognosis evaluation and the like can be achieved. The in-vivo targeting performance of the probe is excellent.
Owner:HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products